Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SPARC's Board approved audited standalone and consolidated financial results for Q4 and FY25. Revenue from operations for FY25 stood at Rs 7,177 lakhs, down from Rs 7,555 lakhs a year ago, while the company reported a net loss of Rs 34,522 lakhs (standalone), slightly narrower than the Rs 38,811 lakhs loss in FY24. Q4 FY25 revenue jumped to Rs 2,719 lakhs from Rs 1,656 lakhs in Q4 FY24, and the quarterly loss narrowed sharply to Rs 6,098 lakhs from Rs 10,669 lakhs. The company disclosed that its 'going concern' status relies on a support letter from its promoter group entity, as it has been incurring cash losses. The Board also approved raising up to Rs 1,800 crores through securities, subject to shareholder approval.
For shareholders, the stock remains in a loss-making, R&D-heavy phase with negative reserves (other equity of Rs -25,307 lakhs) and rising borrowings (total debt around Rs 25,800 lakhs vs Rs 4,700 lakhs last year), which dilutes concerns about dilution from the proposed Rs 1,800 crore fund raise. Operating cash flow remains deeply negative at Rs -36,241 lakhs, and continued operations depend on promoter support, making this a high-risk but event-driven announcement that could move the stock.